Date
26 September 2023
Who Wins If India’s Patent Rules For Drugs Are Amended?
Nushaiba Iqbal writes for India Spend, in an article looking at the proposed amendments to patent laws and their effects on India’s drug exports and public health. She spoke to Claudia Martínez, who leads the Foundation's Generic & Biosimilar Medicines Programme.
Direct links
Generic manufacturers play a specific role and need to be ready to step in and produce life-saving medicines once innovator product patents expire, so that those living in low- and middle-income countries can access treatment without further challenges.
Claudia said: “However, when originator companies try to extend the life of their patents in those countries where they are filed and enforced, this not only causes significant delays in generic availability but can also jeopardise affordable access.”
Read the Foundation's report on generic and biosimilar medicine manufacturers.